COVID 2019 asymptomatic infections are Time Bomb for future

COVID 2019 asymptomatic infections across the World can it be a Time Bomb for Future Pandemic Recurrence?

Background: COVID 2019 Infection can be considered a disease typically following the Iceberg Phenomenon, where many submerged cases are inside and can become a threat to human beings as immunity development to SARS –CoV-2 cannot be forever. Studies across the world have suggested that out of many important research questions- the problem of asymptomatic and presymptomatic virus shedding is one of the grayest areas in the management of the COVID 20019 pandemic across the world.

Objective: Unrecognized threat of Incubatory carriers and asymptomatic cases becoming a re-infection pool to the Global Community can be perilous for the whole world. So a strategy for further Management of asymptomatic and presymptomatic CORONA +ve cases needs urgent appraisal if we have to prevent future recurrence of COVID 2019 Pandemic. That why systematic research is crucial in this regard, as attempted by authors in this article.
Material & methods: As per PRISMA(2009) guidelines protocol, a search of various kinds of studies in any form; using five key search words: ‘Asymptomatic,’
“Presymptomatic” “COVID 2019 Infection Surveillance, Pandemic, Recurrence ” was done in all health-related websites of Google, PubMed, EMBASE, MEDLINE, Global Health, Biomed-Central, Web of Science, Cochrane Library, world library – World-Cat, from 1 January 2020 to 25th April 2020 for systematic-review, followed by MetaAnalysis.
Results: Out of a wide variety of 31 studies available in literature related to this topic,20 were eligible for issues synthesis, from which 2 central themes of Surveillance of Symptomatic and Asymptomatic & Presymptomatics emerged. Symptomatic surveillance was good in the form of Isolation and Quarantine across the World. Still, the real problem was of Asymptomatic post-discharge surveillance, which was only in the nascent stage in many countries worldwide, including developing countries such as India.

Conclusion: Lack of asymptomatic post-discharge surveillance may cause real havoc in the future if no strategy is chalked out by governments across the World, leading to possible recurrence of the COVID 2019 Pandemic. However, the authors suggest more future research studies before saying very definitively that it will certainly happen.

Discussion
Symptomatic transmission refers to transmission from a person while they are experiencing symptoms. Preliminary data suggests that people may be more contagious around the time of symptom onset than later on in the disease. In a small number of case reports and studies, the pre-symptomatic transmission has been documented through contact tracing efforts and enhanced investigation of clusters of confirmed cases. 12-17 This is supported by data suggesting that some people can test positive for COVID-19 from 1-3 days before developing symptoms.6,16 Thus, it is possible that people infected with COVID-19 could transmit the virus before significant symptoms develop. It is important to recognize that presymptomatic transmission still requires the virus to be spread
via infectious droplets or through touching contaminated surfaces. There are few reports of laboratory-confirmed cases that are truly asymptomatic, and to date, there has been no documented asymptomatic transmission. This does not exclude the possibility that it may occur. Asymptomatic cases have been reported as part of contact tracing efforts in some countries. COVID-19 infection so can range from asymptomatic and mild illness to severe illness. Most of the patients have an uncomplicated illness, mild to moderate pneumonia. China CDC has published data on COVID-19, which showed 80.9% of cases were mild [21]. New evidence has emerged from China indicating that most coronavirus infections do not result in symptoms [22]. In summary, there are variations
across individuals in the clinical manifestations of COVID19, and we should pay attention to how to prevent people from being infected by asymptomatic patients and patients who were in their incubation period. Many patients infected with the virus who show few or no symptoms—estimated to be as high as 80% — complicates fighting the disease, forcing health care workers worldwide to shift their focus from containing the disease to mitigation [23].

There is clear evidence of asymptomatic infection with COVID-19. Estimates of the proportion of laboratory-confirmed cases who are asymptomatic may vary by age group, study the setting, and study methodology ranging from 1.2% (China), 6.4% (Italy), 12.9% (pediatric cases in China), 13.0% (long-term care facility in Washington State), and 17.9% (modeled estimate based on data from the Diamond Princess cruise ship). The extent to which screening is undertaken in group exposures and for contacts of cases and the duration of follow-up to ensure asymptomatic individuals do not subsequently develop symptoms will also influence the proportion of asymptomatic cases. There is limited evidence of transmission from asymptomatic people and never develop symptoms and more evidence of transmission from people in their incubation period (i.e., people who transmit infection while asymptomatic but before they develop symptoms) [24]. Globally, too, there is enough evidence that suggests that people who never develop symptoms can transmit the virus. Studies from around the world published in the past weeks reveal the spread by “invisible sources” as a fresh challenge in the fight against Covid-19. This makes it much harder to trace and isolate everyone with the disease before transmitting it to others. Public health experts say these invisible sources of contagion must be fact [2]. Persons with co-morbidities should be shielded from close contact with mobile members of the family,” he said. Earlier, the WHO said that the new coronavirus’s pre-symptomatic or asymptomatic transmission was “relatively rare.” However, new studies from Japan, Italy, South Korea, and Washington state — have suggested that silent spreaders can be just as dangerous to a community.[z2]Although COVID-19 causes only mild illness for most people, it can make some people very ill. More rarely, the disease can be fatal. Older
people and those with preexisting medical conditions (such as high blood pressure, heart problems, or diabetes) appear to be more vulnerable. Public health efforts are targeted at both interrupting further transmission and monitoring the spread of COVID-19. As reports of asymptomatic cases increase, the need for reliable serology testing is becoming more urgent. Several groups are working on this, and developments are being monitored [25]. Researchers also suspect that there is an undetected pool of people who have mild or no symptoms. That is because an increasing number of infected people have not traveled to epidemic hotspots or come into contact with people with confirmed cases of COVID-19.

This is different from unreported cases, those that are missed because authorities are not carrying out enough tests or people in the early stages of the virus who are not yet showing symptoms. A new study suggests there were 37,400 people with the virus in Wuhan who authorities did not know about and who had mild or no symptoms but could still be contagious [5] In Iceland, which says it has tested a higher proportion of inhabitants than any other country,
about half those who tested positive for COVID-19 have no symptoms. Separately, the South China Morning Post reports that the number of “silent carriers” – people infected by the new coronavirus but show delayed or no symptoms –could be as high as one-third of those who test positive [5]. Now researchers are trying to determine whether people infected with COVID-19 but that show no symptoms can infect others. Preliminary findings seem to suggest they can. A study by Yuanyuan Xing et al. [26] from China reveals that after fulfilling the Chinese current criteria for discharge, it took few days for the immune system to eliminate the residual viruses in the body. During this period, the virus may rebound and test positive, but the patients were asymptomatic, and
chest CT showed no deterioration. If the patients’ immunity decreases, there is a risk of a relapse. The new revelation of asymptomatic or mildly symptomatic infection in developing countries such as India has also generated Urgent concerns with the ICMR body. While ICMR officials do not recommend mass testing in India, given the size and scale of the country, experts familiar with the development said the door-to-door surveillance model is being examined.“It’s not easy to test everyone. But the model of door-to-door surveillance used for polio can be replicated here. The fact that India continues to be polio-free indicates the robustness of the case of Covid-19, the possibility of monitoring people aged 50 years and more is being considered. “The silent spreaders are unknowingly infecting others. There is a need to strictly monitor the 50 plus population, which has the most positive cases,” added this person. Any such
exercise will take a long time and be expensive. Door-to-door surveillance will prove to be “costly and unachievable” in a country like India. According to WHO(2020) report that Countries that routinely conduct primary care or hospital-based sentinel surveillance for ILI, ARI, SARI, or pneumonia should continue to collect the respiratory specimens using existing case definitions through sentinel or syndromic networks. Laboratories should continue testing routine sentinel site samples and non-sentinel samples for influenza, with the addition of testing for COVID-19. Until we know more about the temporal patterns of transmission, all countries are encouraged to conduct year-round surveillance for COVID-19. It is recommended to use the WHO’s case definition for ILI and SARI for COVID-19 surveillance.

Some COVID-19 infections may probably be missed due to the requirement of fever as a criterion. This is
acceptable since we monitor general trends and do not estimate the burden of illness, and fever will likely
enrich the viral yield. The following strategies can be utilized to strengthen asymptomatic surveillance GISRS surveillance: Influenza and COVID-19 are both respiratory viruses with similar clinical presentations. GISRS is a well-established network of more than 150 national public health laboratories in 125 countries on influenza and viruses’ epidemiology and virologic evolution. Until 25 March 2020, approximately 85% of more than 220 national public health laboratories currently testing
for COVID-19 globally are closely associated with GISRS. Utilizing the GISRS system can be an efficient and cost-effective approach to enhancing COVID-19 surveillance.
a) Developed countries( e.g. US)
a) Outpatient Influenza-Like Illness Network (ILINet) and
National Syndromic Surveillance Program (NSSP)
b)National Polio Surveillance Programmes
b) Developing Countries ( e.g., India) a) NPSP based surveillance system
b) AADHAR BASED IDSP Surveillance
c) Door to Door Surveillance by Primary Health care Workers
d) Sentinel Surveillance at CHC/Block level

National surveillance systems should initially aim at rapidly detecting cases and assessing community transmission. As the epidemic progresses, surveillance should monitor the intensity, geographical spread, and impact of the epidemic on the population and healthcare systems and assess the effectiveness of measures in place. In the circumstances with capacity shortages and strict implementation of social distancing measures, surveillance should focus on severe acute respiratory infections, sentinel surveillance in outpatient clinics, or data collection through telephone helplines. A strategic approach based on an early and rigorous application of these measures will help reduce the burden and pressure on the healthcare system and hospitals. It will allow more time for the testing of therapeutics and vaccine development [27]. According to WHO( 2020) Report [x], any global surveillance’s ultimate objectives should be to 1. Monitor trends in COVID-19 disease at national and global levels. 2. Rapidly detect new cases in countries where the virus is not circulating, and monitor cases in countries where the virus has started circulating. 3. Provide epidemiological information to conduct risk assessments at the national, regional, and global levels. 4. Provide epidemiological information to guide preparedness and response measures. Such surveillance strategies need replication regarding asymptomatics if we have to prevent future recurrence of COVID 2019 Global Pandemic. In China, it is now followed that the Designated hospitals
should make plans for patients’ return visits and re-testing for the next two to four weeks following their discharge; the sputum samples are more reliable and should be the first choice for re-testing. A high-powered committee headed by Chinese Premier Li Keqiang, leading the efforts to contain the virus since January, has also called for intensified detection and prompt response to asymptomatic cases meaning people infected with coronavirus but showed no symptoms. Screening of asymptomatic infections should be stepped up, targeting close contacts of confirmed patients, people involved in cluster outbreaks, those exposed to Covid-19, and travelers from areas with high risks of infections, it said. The regulation required nationwide hospitals and disease control departments to take prompt actions once asymptomatic carriers are detected. Once verified, asymptomatic carriers will be put under
concentrated medical observation for 14 days and can only. India’s Discharge Policy of nCoV Cases also needs reconsideration. If the laboratory results for nCOV are negative, the discharge of such patients will be governed by his provisional/confirmed diagnosis, and it is up to the treating physician to make a decision. The case shall still be monitored for 14 days after their last contact with a confirmed 2019-nCoV case. The case shall be discharged only after evidence of chest radiographic clearance and viral clearance in respiratory
samples after two specimens test negative for nCOV within a period of 24 hours. India’s top medical research body is grappling with the
problem posed by “silent spreaders” and examining the feasibility of starting ‘door-to-door’ surveillance to monitor and test older people at high risk who don’t have symptoms [22]. While ICMR officials do not recommend mass testing in India, given the size and scale of the country, experts familiar with the development said the door-to-door surveillance model is being examined.
Salivary Surveillance can also be a new Option. Because patients can provide saliva without any invasive procedures,
the use of saliva specimens will reduce the risk of nosocomial transmission of 2019-n CoV and is ideal for situations in which
nasopharyngeal specimen collection may be contraindicated. As per a study in literature, Saliva can be a promising noninvasive
specimen for diagnosis, monitoring, and infection control in patients with 2019-nCoV infection [28]. Our systematic review reveals that, as per recommendations from many studies-Asymptomatic carriers during the incubation period can be a potential infection source of
COVID-19. As Person-to-person transmission has been documented, asymptomatic carriers should be a focus for disease prevention. So it gets almost clear from studies in literature- asymptomatic carriers can transmit COVID-19 during the incubation period [29-35]. Therefore, our systematic review finally reveals that both developed & developing countries such as India lack a Proper Post Discharge Surveillance system of Asymptomatic Corona + ve cases, which can be detrimental in the future recurrence of Epidemics in countries like India where the Population density is high. Virus explosive Hot spot areas such as the Dharavi Slum of Mumbai & Slums of Delhi can be a dangerous recurrent area in the future [35-44].

Conclusion: Lack of asymptomatic post-discharge surveillance can be devastating for the future if no Proper-surveillance strategy
is chalked out by governments across the World, leading to possible recurrence of the COVID 2019 Pandemic. However, the authors
suggest more research studies in the future on an urgent basis before saying it very definitively.

References:

No symptoms in 80% of Covid cases raise concerns. Link: https://bit.ly/32saVZC
Chan JFW, Yuan S, Kok KH, To KKW, Chu H, et al. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395: 514-523. Link: https://bit.ly/34IPJBg
Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY (2020) SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci 10: 40. Link: https://bit.ly/31zLc1Y
Lauer SA, Grantz KH, Bi Q, Jones FK, Jones FK, Zheng Q, et al. (2020) The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. Link: https://bit.ly/2Qt4EqW
Bai Y, Yao L, Wei T, Tian F, Jin DY, et al. (2020) Presumed asymptomatic carrier transmission of COVID-19. JAMA 323: 1406-1407. Link: https://bit.ly/3gAFDok
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, et al. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270-273. Link: https://go.nature.com/34EASYx
Lam TTY, Shum MHH, Zhu HC, Tong YG, Ni XB, et al. (2020) Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. BioRxiv. Link: https://bit.ly/32sPAiG
Lu R, Zhao X, Li J, Niu P, Yang B, et al. (2020) Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. Link: https://bit.ly/2Qvy5sD
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team Vital surveillances (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China. China CDC Weekly. 2: 113-122.
Wang D, Hu B, Hu C, Zhu F, Liu X, et al. (2020) Clinical characteristics of 138 hospitalized patients with 2019, novel coronavirus–infected pneumonia in Wuhan China. JAMA 323: 1061-1069. Link: https://bit.ly/34FqYpF
Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – sixth update. Link: https://bit.ly/3gz4vwU
CDC COVID Data Tracker. CDC. Link: https://bit.ly/2YY70TB
Heimdal I, Moe N, Krokstad S, Christensen A, Skanke LH, et al. (2019) Human coronavirus in hospitalized children with respiratory tract infections: a 9-year population-based study from Norway. J Infect Dis 219: 1198–1206. Link: https://bit.ly/3gCU5Mw
Chan JFW, Yuan S, Kok KH, To KKW, Chu H, et al. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395: 514-523. Link: https://bit.ly/34IPJBg
WHO (2020) Global surveillance for COVID-19 caused by human infection with COVID-19 virus. Link: https://bit.ly/2Ey3RTk
Heneghan C, Brassey J, Jefferson T (2020) COVID-19: What proportion are asymptomatic?. Link: https://bit.ly/2EKvGY5
Heneghan C, Brassey J, Jefferson T (2020) COVID-19: What proportion are asymptomatic?. Link: https://bit.ly/2EKvGY5
Hu Z, Song C, Xu C, Jin G, Chen Y, et al. (2020) Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 63: 706-711. Link: https://bit.ly/2QtMC80
Day M (2020)Covid-19: four-fifths of cases are asymptomatic, China figures indicate. BMJ 369: m1375. Link: https://bit.ly/2Da4y4C
Coronavirus disease 2019 (COVID-19) Situation Report – 73. Link: https://bit.ly/3gysZ9n
Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323: 1239–1242. Link: https://bit.ly/2Ezoq1x
Nishiura H, Kobayashi T, Suzuki A, Jung SM, Hayashi K, et al. (2020) Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). International Journal of Infectious Diseases 94: 154-155. Link: https://bit.ly/2EqEK4Z
Lai CC, Liu HY, Wang CY, Hsueh SC, Yen MY, et al. (2020) Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. Journal of Microbiology, Immunology and Infection 53: 404-412. Link: https://bit.ly/2YH3EEc
Sibylle BS, Patrick R, Yassoungo S, Alexandra M, Christine C, et al. (2020) First coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill 25: pii=2000094. Link: https://bit.ly/2QwfjkL
Wu JT, Leung K, Leung GM (2020) Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modeling study. Lancet 395: 689–697. Link: https://bit.ly/32sRHmC
Rahman S, Bahar T (2020) COVID-19: The New Threat. Int J Infect 7: e102184. Link: https://bit.ly/3b0Z0py
WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 38. Link: https://bit.ly/2Qw4DCF
Cases of Coronavirus Disease (COVID-19) in the U.S.
COVID-19 – What We Know So Far Abou. Asymptomatic Infection and Asymptomatic Transmission. Public health Ontario. Link: https://bit.ly/2Da5QfY
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, et al. (2020) Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infectious Diseases. Link: https://bit.ly/34GGZeQ
Kenji M, Katsushi K, Alexander Z, Gerardo C (2020) Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 25: pii=2000180. Link: https://bit.ly/3jq6GVp
Yuanyuan X, Pingzheng M, Yu X, Oiu Z, Yongxi Z, et al. (2019) Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. Euro Surveill 25: pii=2000191. Link: https://bit.ly/31AnPFF
Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, et al. (2020) World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 76: 71-76. Link: https://bit.ly/32wJtKn
Lin CY, Cheng CH, Lu PL, LO HH, Tsai MJ, et al. (2020) Active Surveillance for Suspected COVID-19 Cases in Inpatients with Information Technology. Journal of Hospital Infection 105: 197-199. Link: https://bit.ly/2YHijiA
Lorenz Z (2020) Case Study Shows Asymptomatic Transmission of COVID-19 in China. Clinical Infectious Diseases. Link: https://bit.ly/32x3b8H
NJDOH Surveillance criteria and testing. Link: https://bit.ly/3hDyyEL
WHO (2020) Interim guidance.Global Surveillance for human infection with coronavirus disease (COVID-19). Link: https://bit.ly/32yUOJS
WHO (2020) Interim guidance. Operational considerations for COVID-19 surveillance using GISRS. Link: https://bit.ly/3lq13Im
Xing Y, Mo P, Xiao Y, Zhao O, Zhang Y, et al. (2020) Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China. Euro Surveill 25: pii=2000191. Link: https://bit.ly/2EHP2xj
Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, et al. (2020) Hospitalization Rates and Characteristics of Patients Hospitalized with laboratory-confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 69: 458–464. Link: https://bit.ly/2YHXzqX
China orders re-test of recovered Covid-19 patients intensified screening of asymptomatic cases. Link: https://bit.ly/2YIVRpl
Ye F, Xu S, Rong Z, Deng P, Liu H, et al. (2020) Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster. International Journal of Infectious Diseases 94: 133-138. Link: https://bit.ly/34MKqRc
To KKW, Tsang OTY, Yip CCY, Chan KH, Wu TC, et al. (2020) Consistent Detection of 2019 Novel Coronavirus in Saliva, Clinical Infectious Diseases 71: 841-843. Link: https://bit.ly/2YHYckj
Popay J, Rogers A, Williams G (1998) Rationale and standards for the systematic review of qualitative literature in health services research. Qualitative Health Research 8: 341-351. Link: https://bit.ly/3lnNnO5

https://www.diabetesasia.org/magazine/category/covid19/

More Information:https://www.covid19india.org/

1.https://www.cdc.gov/coronavirus/2019-nCoV/index.html

2.https://www.who.int/publications/m/item/COVID-19-and-NCDs

3.https://www.who.int/emergencies/diseases/novel-coronavirus-2019

4. https://www.who.int/

5. https://blog.covid19india.org/

6. https://www.covid19india.org/about

7. https://twitter.com/covid19indiaorg

8.https://t.me/covid19indiaorg

9.https://www.mohfw.gov.in/

10.

WHO Coronavirus Disease (COVID-19) Dashboard

https://covid19.who.int/?gclid=CjwKCAjwkdL6BRAREiwA-kiczFSgq5kU1VD8uV3753Ow5835An5vJfAnuka7JVJOCDX2AlQze-ym_BoCLlEQAvD_BwE9.https://api.covid19india.org/

About Post Author

Profile

Author's Latest Posts

Dr. Rajesh Jain

Dr. Rajesh Jain MD PG Diploma Diabetes, UK

The diabetesasia is the advocate for the people currently living with diabetes Burden & NCDs Risk. Global Diabetes Walk campaign remind us to Prevent diabetes.

See author's posts